Infinity Pharmaceuticals
Presence
Infinity Pharmaceuticals is a company listed under the stock ticker INFI (US).
Acquisition, funding and merger involving Infinity Pharmaceuticals.
- Infinity Pharmaceuticals has filed for bankruptcy protection (posted on October 2 2023).
- MEI Pharma has announced the acquisition of Infinity Pharmaceuticals (posted on February 24 2023).
Executives
View the org chart displaying its 10 main executives
Most searched biographies at Infinity Pharmaceuticals
Popular executive movements at Infinity Pharmaceuticals
- Adelene Perkins, Chairman of the Board, President, Chief Executive Officer, has left the company (posted on September 5 2023).
- Robert Ilaria, Chief Medical Officer, has left the company (posted on September 5 2023).
Create your alert
to follow the executive moves at Infinity Pharmaceuticals.
Biotechnology
Infinity Pharmaceuticals has 2,281 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Infinity Pharmaceuticals
- Press Releases | Infinity Pharmaceuticals, Inc.
- Infinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast | Infinity Pharmaceuticals, Inc.
- Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference | Infinity Pharmaceuticals, Inc.
- Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results | Infinity Pharmaceuticals, Inc.
- Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast | Infinity Pharmaceuticals, Inc.
- Press Releases | Infinity Pharmaceuticals, Inc.
- Infinity Receives Fast Track Designation for Eganelisib in Combination with a Checkpoint Inhibitor and Chemotherapy for First-Line Treatment of Advanced TNBC | Infinity Pharmaceuticals, Inc.
- Infinity to Present at Upcoming Investor Conferences in September | Infinity Pharmaceuticals, Inc.
- Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results | Infinity Pharmaceuticals, Inc.
- Infinity Announces the Date of Its Second Quarter Financial Results Conference Call and Webcast | Infinity Pharmaceuticals, Inc.
- View more press releases Close
Social media about Infinity Pharmaceuticals
- Infinity Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Infinity Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Seth Tasker 
Call Infinity Pharmaceuticals at +1 617...
